Global Pharmaceutical Industry Growth Opportunities

Global Pharmaceutical Industry Growth Opportunities

2021 Highlights and What to Expect in 2022

RELEASE DATE
02-Dec-2021
REGION
North America
Research Code: MG4D-01-00-00-00
SKU: HC03481-NA-MT_26028
$2,450.00
In stock
SKU
HC03481-NA-MT_26028
$2,450.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond.

It addresses the impact of innovative modalities, technologies, and recent drug approvals, such as gene and cell therapy, monoclonal antibodies,
RNA-based therapeutics, and the increasing use of health data through real-world evidence and artificial intelligence. The need to gain access to early-stage drugs and novel technologies has led to a higher rate of licensing and mergers with small biopharma that are developing the same. In addition, patient engagement has been driving digital partnerships centered around digital therapeutics, decentralized clinical trials, remote monitoring, and telemedicine.

The study also provides critical insights into the key regulatory, reimbursement, and policy updates for 2021, ranging from health data standardization and quality regulation to direct drug pricing negotiations and biosimilars & generics encouragement.

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Strategic Imperative 8™ on the Pharmaceuticals Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Pharmaceuticals—Factors Affecting Growth

Growth Opportunity Analysis for the Global Pharmaceutical Industry

2021 Highlights and What to Expect in 2022

2021 Highlights and What to Expect in 2022 (continued)

2021 Highlights and What to Expect in 2022 (continued)

Growth Drivers

Growth Restraints

Market Snapshot—Next-generation Biologics Modalities

Key FDA Approvals for Novel Drugs

Key FDA Approvals for Novel Drugs (continued)

Key FDA Approvals for Novel Drugs (continued)

Key FDA Approvals for Novel Drugs (continued)

Key FDA Approvals for Novel Drugs—Takeaways

Key M&A Deals

Key M&A Deals in the Pharma Industry—Takeaways

Key Product Licensing Deals

Key Product Licensing Deals (continued)

Key Product Licensing Deals (continued)

Key Product Licensing Deals—Takeaways

Key Digital Partnership Deals

Key Digital Partnership Deals (continued)

Key Digital Partnership Deals—Key Takeaways

Key Digital Partnership Deals—Key Takeaways (continued)

Key Regulatory, Reimbursement, and Policy Updates

Key Regulatory, Reimbursement, and Policy Updates (continued)

Key Regulatory, Reimbursement, and Policy Updates (continued)

Key Regulatory, Reimbursement, and Policy Updates (continued)

Key Regulatory, Reimbursement, and Policy Updates (continued)

Key Regulatory, Reimbursement, and Policy Updates (continued)

Key Regulatory, Reimbursement, and Policy Updates—Takeaways

Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity

Growth Opportunity 1: Novel Drug Modalities and RNA Therapeutics Transforming R&D Productivity (continued)

Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience

Growth Opportunity 2: Integrated and RWE-supported Drug Development Platforms/Solutions to Improve User Experience (continued)

List of Exhibits

Legal Disclaimer

Related Research
The global pharmaceutical industry is witnessing dynamic trends following the coronavirus pandemic and is adapting to new challenges and opportunities. This study analyzes the 2021 highlights in the global pharmaceutical industry and provides forecasts for the next year and beyond. It addresses the impact of innovative modalities, technologies, and recent drug approvals, such as gene and cell therapy, monoclonal antibodies, RNA-based therapeutics, and the increasing use of health data through real-world evidence and artificial intelligence. The need to gain access to early-stage drugs and novel technologies has led to a higher rate of licensing and mergers with small biopharma that are developing the same. In addition, patient engagement has been driving digital partnerships centered around digital therapeutics, decentralized clinical trials, remote monitoring, and telemedicine. The study also provides critical insights into the key regulatory, reimbursement, and policy updates for 2021, ranging from health data standardization and quality regulation to direct drug pricing negotiations and biosimilars & generics encouragement.--BEGIN PROMO--

Key Issue Addressed

  • What should we expect in the global pharmaceutical industry in 2022

 

More Information
No Index No
Podcast No
Author Delfina Huergo
Industries Healthcare
WIP Number MG4D-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,9568-B1,9611-B1